ArticleScientific reports2025
Probenecid relieves LPS-induced neuroinflammation by modulating the NLRP1 inflammasome pathway in BV2 cells.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Probenecid is a dual-acting antiviral/anti-inflammatory therapy for diverse respiratory viruses.Frontiers in pharmacology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Inflammation is a key factor in neurodegenerative diseases (NDs) development, such as Alzheimer's disease (AD) and Parkinson's disease (PD). Microglial cells maintain immune microenvironment homeostasis in the central nervous system (CNS) and are actively involved in neuroinflammation. Therefore, inhibiting microglia-mediated neuroinflammation may provide therapeutic benefits in treating NDs. Probenecid (Prob), a sulfonamide derivative, has demonstrated neuroprotective and anti-inflammatory properties. This study investigated the anti-inflammatory and antioxidative properties of Prob in a neuroinflammatory model which was established by stimulating BV2 cells with lipopolysaccharide (LPS). The oxidative stress was assessed by measuring the nitric oxide (NO), reactive oxygen species (ROS), superoxide dismutase (SOD), and malondialdehyde (MDA) levels. Tumor necrosis factor-α (TNF-α) and interleukin-1β (IL-1β) were quantified using enzyme-linked immunosorbent assay (ELISA) and RT-qPCR. The wound-healing assay and phagocytosis assay were employed to examine the migration and phagocytosis capacity of BV2 cells, respectively. The mRNA expression of CD16, CD206, iNOS, and Arg-1 was measured using RT-qPCR, while Western blot was used to analyze inflammasome-associated protein levels. The results indicated that Prob suppressed LPS-induced microglial activation and reduced TNF-α and IL-1β production. Moreover, Prob attenuated the migration and phagocytosis capacities of BV2 cells and inhibited oxidative stress. Prob regulated the immune microenvironment, as shown by reduced M1 markers (iNOS and CD16) and increased M2 markers (Arg-1 and CD206). However, the NLRP1 inflammasome activator (muramyl dipeptide, MDP) reversed the effects of Prob. In conclusion, Prob could alleviate LPS-induced inflammation by modulating the NLRP1 inflammasome pathway.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.